[go: up one dir, main page]

ZA201000676B - Pyrrolidine aryl-ether as NK3 receptor antagonists - Google Patents

Pyrrolidine aryl-ether as NK3 receptor antagonists

Info

Publication number
ZA201000676B
ZA201000676B ZA201000676A ZA201000676A ZA201000676B ZA 201000676 B ZA201000676 B ZA 201000676B ZA 201000676 A ZA201000676 A ZA 201000676A ZA 201000676 A ZA201000676 A ZA 201000676A ZA 201000676 B ZA201000676 B ZA 201000676B
Authority
ZA
South Africa
Prior art keywords
ether
receptor antagonists
pyrrolidine
aryl
pyrrolidine aryl
Prior art date
Application number
ZA201000676A
Other languages
English (en)
Inventor
Philippe Jablonski
Kenichi Kawasaki
Henner Knust
Anja Limberg
Matthias Nettekoven
Hasane Ratni
Claus Riemer
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA201000676B publication Critical patent/ZA201000676B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA201000676A 2007-08-07 2010-01-28 Pyrrolidine aryl-ether as NK3 receptor antagonists ZA201000676B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113942 2007-08-07

Publications (1)

Publication Number Publication Date
ZA201000676B true ZA201000676B (en) 2010-10-27

Family

ID=39865446

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201000676A ZA201000676B (en) 2007-08-07 2010-01-28 Pyrrolidine aryl-ether as NK3 receptor antagonists

Country Status (19)

Country Link
US (1) US8012998B2 (xx)
EP (1) EP2185540B1 (xx)
JP (1) JP2010535733A (xx)
KR (1) KR101167774B1 (xx)
CN (1) CN101778837A (xx)
AR (1) AR067808A1 (xx)
AT (1) ATE517100T1 (xx)
AU (1) AU2008285718A1 (xx)
BR (1) BRPI0815658A2 (xx)
CA (1) CA2695211A1 (xx)
CL (1) CL2008002293A1 (xx)
ES (1) ES2367464T3 (xx)
IL (1) IL203363A (xx)
MX (1) MX2010001080A (xx)
PE (1) PE20090898A1 (xx)
RU (1) RU2010106974A (xx)
TW (1) TW200916456A (xx)
WO (1) WO2009019163A1 (xx)
ZA (1) ZA201000676B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519738T1 (de) * 2007-08-22 2011-08-15 Hoffmann La Roche Pyrrolidinarylether als nk3-rezeptorantagonisten
JP5399518B2 (ja) 2009-01-30 2014-01-29 エフ.ホフマン−ラ ロシュ アーゲー Nk3レセプターアンタゴニストとしてのピペリジン誘導体
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
WO2011048525A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
US8507535B2 (en) 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
ES2838573T3 (es) 2014-08-21 2021-07-02 Bristol Myers Squibb Co Derivados de benzamida ligados como inhibidores potentes de ROCK
US10246436B2 (en) 2015-09-02 2019-04-02 Trevena, Inc. 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
CN105399661A (zh) * 2015-12-14 2016-03-16 华东师范大学 2,6-二溴甲基吡啶的制备方法
US11178872B2 (en) 2016-05-09 2021-11-23 Nippon Soda Co., Ltd. Cyclic amine compound and pest control agent
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
JP7316216B2 (ja) * 2017-02-17 2023-07-27 トレベナ・インコーポレイテッド 5員アザ複素環を含有するデルタ-オピオイド受容体調節化合物、その使用方法及び製造方法
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU506399B2 (en) 1975-12-30 1980-01-03 Showa Denko Kabushiki Kaisha 3-(2-aryl-2-propyl) ureas
IN148482B (xx) 1977-06-03 1981-03-07 Pfizer
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE364606T1 (de) 1993-12-29 2007-07-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
MXPA04011730A (es) * 2002-05-31 2005-07-14 Takeda Pharmaceutical Derivados de piperidina, proceso para producir el mismo, y uso.
HRP20070471T3 (hr) 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
WO2005032464A2 (en) * 2003-09-30 2005-04-14 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
EP1705176A4 (en) * 2004-01-14 2009-06-03 Takeda Pharmaceutical CARBOXYLAMIDE DERIVATIVE AND ITS USE
US7138423B2 (en) * 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
KR100939347B1 (ko) 2005-07-20 2010-01-29 (주)카이로드 광학적으로 순수한 (s)-3-히드록시 피롤리딘의 제조방법

Also Published As

Publication number Publication date
MX2010001080A (es) 2010-03-01
CL2008002293A1 (es) 2009-05-29
EP2185540A1 (en) 2010-05-19
IL203363A (en) 2013-03-24
PE20090898A1 (es) 2009-07-13
US8012998B2 (en) 2011-09-06
CN101778837A (zh) 2010-07-14
ES2367464T3 (es) 2011-11-03
RU2010106974A (ru) 2011-09-20
AR067808A1 (es) 2009-10-21
KR101167774B1 (ko) 2012-07-24
TW200916456A (en) 2009-04-16
WO2009019163A1 (en) 2009-02-12
EP2185540B1 (en) 2011-07-20
KR20100045502A (ko) 2010-05-03
CA2695211A1 (en) 2009-02-12
US20090042896A1 (en) 2009-02-12
BRPI0815658A2 (pt) 2015-02-18
AU2008285718A1 (en) 2009-02-12
JP2010535733A (ja) 2010-11-25
ATE517100T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
IL198825A0 (en) Substituted diazepan compounds as orexin receptor antagonists
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
IL208466A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL201165A0 (en) CRIg ANTAGONISTS
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
IL212545A0 (en) Toll-like receptor 3 antagonists
ZA200903334B (en) Substituted diazepan compounds as orexin receptor antagonists
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
ZA201103119B (en) Isoquinolinone derivatives as nk3 antagonists
IL212107A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL209663A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
IL209266A0 (en) Pyrrolidine derivatives as nk2 receptor antagonists
ZA200904479B (en) Nitroderivatives as angiotensin II receptor antagonists
IL217759A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
IL202454A0 (en) Urotensin ii receptor antagonists
IL207700A0 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists
IL213763A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
IL213769A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
IL211803A0 (en) Quinazoline derivatives as nk3 receptor antagonists
GB0701632D0 (en) MET receptor antagonists